journal article·2023-03-13

Hydrogel-Bondable Asymmetric Planar Membranes with Hierarchical Pore Structures for Cell Scaffolding and Encapsulation

Yi Wang, Kai Wang, Ying Luo, Haifeng Chen

Publisher page

Abstract

Biomaterials for cell replacement therapy could facilitate the delivery, function, and retrieval of transplanted therapeutic cells. However, the limited capacity to accommodate a sufficient quantity of cells in biomedical devices has hindered the success of clinical application, resulting from the suboptimal spatial organization of cells and insufficient permeation of nutrients in the materials. Herein, through the immersion-precipitation phase transfer (IPPT) process from polyether sulfone (PES), we develop planar asymmetric membranes with a hierarchical pore architecture spanning from nanopores (∼20 nm) in the dense skin and open-ended microchannel arrays with gradient pore size increasing vertically from microns to ∼100 μm. The nanoporous skin would be an ultrathin diffusion barrier, while the microchannels could support high-density cell loading by acting as separate chambers allowing uniform distribution of cells in the scaffold. Alginate hydrogel could permeate into the channels and form a sealing layer after gelation, which could slow down the invasion of host immune cells into the scaffold. The hybrid thin-sheet encapsulation system (∼400 μm thick) could protect allogeneic cells over half-year after intraperitoneal (IP) implantation in immune-competent mice. Such structural membranes and plastic-hydrogel hybrids of thin dimensions could find important applications in cell delivery therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Pancreatic function and diabetes · Microfluidic and Bio-sensing Technologies · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering, College of Future Technology, Peking University, Haidian District, Beijing 100871, China

Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing 100191, China

Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States

Funding

National Natural Science Foundation of China

References (60)

Show source-provided references
1. 10.1038/nrendo.2016.17810.1038/nrendo.2016.178 ↗
2. 10.1038/bmt.2011.10510.1038/bmt.2011.105 ↗
3. 10.1002/adma.20200635710.1002/adma.202006357 ↗
4. 10.1002/advs.20200294410.1002/advs.202002944 ↗
5. 10.1038/s41551-018-0235-910.1038/s41551-018-0235-9 ↗
6. 10.1016/j.biomaterials.2017.05.03310.1016/j.biomaterials.2017.05.033 ↗
7. 10.1126/scitranslmed.abb460110.1126/scitranslmed.abb4601 ↗
8. 10.1038/s41551-020-0538-510.1038/s41551-020-0538-5 ↗
9. 10.1038/s42255-020-0269-710.1038/s42255-020-0269-7 ↗
10. 10.1016/j.cell.2007.11.01910.1016/j.cell.2007.11.019 ↗
11. 10.1038/s41551-018-0246-610.1038/s41551-018-0246-6 ↗
12. 10.1038/s41591-021-01645-710.1038/s41591-021-01645-7 ↗
13. 10.1038/nm.403010.1038/nm.4030 ↗
14. 10.1016/j.cell.2014.09.04010.1016/j.cell.2014.09.040 ↗
15. 10.1038/nbt.303310.1038/nbt.3033 ↗
16. 10.1016/S0140-6736(94)90067-110.1016/S0140-6736(94)90067-1 ↗
17. Open-label Investigation of the Safety and Effectiveness of DIABECELL(R) in Patients With Type I Diabetes Mellitus. https://clinicaltrials.gov/ct2/show/NCT00940173 (accessed 2022-08-03).
18. Open-label Investigation of the Safety and Efficacy of DIABECELL in Patients With Type 1 Diabetes Mellitus. https://clinicaltrials.gov/ct2/show/NCT01736228 (accessed 2022-08-03).
19. Open-label Investigation of the Safety and Effectiveness of DIABECELL in Patients With Type 1 Diabetes Mellitus. https://clinicaltrials.gov/ct2/show/NCT01739829 (accessed 2022-08-03).
20. 10.1016/j.addr.2018.04.01810.1016/j.addr.2018.04.018 ↗
21. 10.2337/dc11-073110.2337/dc11-0731 ↗
22. 10.2337/diacare.29.01.06.dc05-127010.2337/diacare.29.01.06.dc05-1270 ↗
23. 10.2337/dc09-074410.2337/dc09-0744 ↗
24. Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients. https://clinicaltrials.gov/ct2/show/study/NCT00260234 (accessed 2022-08-03).
25. 10.1002/jbm.82029120810.1002/jbm.820291208 ↗
26. 10.1089/ten.teb.2018.012410.1089/ten.teb.2018.0124 ↗
27. 10.1177/153537021664712910.1177/1535370216647129 ↗
28. 10.1111/ajt.1464210.1111/ajt.14642 ↗
29. 10.1055/s-0030-126791610.1055/s-0030-1267916 ↗
30. 10.5500/wjt.v6.i1.6910.5500/wjt.v6.i1.69 ↗
31. 10.1038/nrd.2016.23210.1038/nrd.2016.232 ↗
32. 10.1016/S1471-4914(02)02381-X10.1016/S1471-4914(02)02381-X ↗
33. 10.1016/j.stem.2018.05.01610.1016/j.stem.2018.05.016 ↗
34. 10.1126/science.176332810.1126/science.1763328 ↗
35. 10.1097/MAT.0b013e3181a8deba10.1097/MAT.0b013e3181a8deba ↗
36. 10.1021/am502046h10.1021/am502046h ↗
37. 10.1039/c3lc50601k10.1039/c3lc50601k ↗
38. 10.1038/s41598-021-84154-410.1038/s41598-021-84154-4 ↗
39. 10.1007/s10544-008-9236-x10.1007/s10544-008-9236-x ↗
40. 10.1038/s41598-017-09647-710.1038/s41598-017-09647-7 ↗
41. 10.1016/j.biomaterials.2018.05.04710.1016/j.biomaterials.2018.05.047 ↗
42. 10.1016/j.stem.2021.10.00310.1016/j.stem.2021.10.003 ↗
43. 10.1016/j.xcrm.2021.10046610.1016/j.xcrm.2021.100466 ↗
44. 10.1038/nbt.346210.1038/nbt.3462 ↗
45. 10.1038/s41551-018-0275-110.1038/s41551-018-0275-1 ↗
46. 10.1111/j.1749-6632.1997.tb52216.x10.1111/j.1749-6632.1997.tb52216.x ↗
47. 10.1126/science.187.4179.84710.1126/science.187.4179.847 ↗
48. 10.1126/science.40764910.1126/science.407649 ↗
49. 10.1016/j.biomaterials.2013.01.00310.1016/j.biomaterials.2013.01.003 ↗
50. 10.1021/acs.biomac.8b0162410.1021/acs.biomac.8b01624 ↗
51. 10.1002/bit.2114010.1002/bit.21140 ↗
52. 10.1016/j.biomaterials.2014.10.03210.1016/j.biomaterials.2014.10.032 ↗
53. 10.1073/pnas.170880611510.1073/pnas.1708806115 ↗
54. 10.1002/btm2.1030010.1002/btm2.10300 ↗
55. 10.1016/j.scr.2009.02.00210.1016/j.scr.2009.02.002 ↗
56. 10.1002/adhm.20220024310.1002/adhm.202200243 ↗
57. 10.1016/j.tips.2021.11.00710.1016/j.tips.2021.11.007 ↗
58. 10.1002/advs.20200370810.1002/advs.202003708 ↗
59. 10.1126/sciadv.abn007110.1126/sciadv.abn0071 ↗
60. 10.1016/j.biomaterials.2020.12023210.1016/j.biomaterials.2020.120232 ↗